A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma |
| |
| Affiliation: | 1. Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia;2. Melanoma Institute Australia, The University of Sydney, Sydney, Australia;3. Centre for Drug Discovery and Development, Cancer Research Institute, University of South Australia, Adelaide, Australia |
| |
| Abstract: | |
| |
| Keywords: | BETi" },{" #name" :" keyword" ," $" :{" id" :" kwrd0015" }," $$" :[{" #name" :" text" ," _" :" BET inhibitor CDK9i" },{" #name" :" keyword" ," $" :{" id" :" kwrd0025" }," $$" :[{" #name" :" text" ," _" :" CDK9 inhibitor GSEA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0035" }," $$" :[{" #name" :" text" ," _" :" gene set enrichment analysis IC50" },{" #name" :" keyword" ," $" :{" id" :" kwrd0045" }," $$" :[{" #name" :" text" ," _" :" half maximal inhibitory concentration |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
